Teacher Retirement System of Texas Buys 1,499 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Teacher Retirement System of Texas raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,241 shares of the company’s stock after purchasing an additional 1,499 shares during the quarter. Teacher Retirement System of Texas’ holdings in Axsome Therapeutics were worth $782,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter valued at approximately $52,000. R Squared Ltd bought a new position in Axsome Therapeutics in the fourth quarter worth $64,000. KBC Group NV lifted its position in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the period. Xponance Inc. lifted its position in Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock valued at $225,000 after buying an additional 277 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $239,000. 81.49% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

AXSM has been the subject of a number of recent research reports. Morgan Stanley lifted their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Truist Financial lifted their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company upped their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Mizuho lifted their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Leerink Partners boosted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $167.64.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $118.53 on Monday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of -19.79 and a beta of 1.00. The stock has a 50-day moving average of $119.67 and a 200 day moving average of $101.22. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.